Surgeons & Cost

The SRS market is split between high-volume gender-affirming centers that have been doing trans bottom surgery for decades, and a much larger field of general urology and plastics practices that have begun adopting the procedure as demand has grown. The technical mechanics overlap substantially; the experience curve, complication-management infrastructure, and post-op support do not. Vaginoplasty is technically demanding, and the volume-outcome relationship that holds across reconstructive surgery holds here too — a tier-1 center charging $40K and a Thai tier-1 center charging $15K are both safer choices than a tier-2 US practice charging $25K.

This page covers surgeon selection and cost only. For specific surgical techniques see Penile-Inversion Vaginoplasty, Peritoneal Pull-Through, Orchiectomy, and Vulvoplasty. For who is and isn't a candidate and how referrals work, see Candidacy & Timing. For sequencing with facial work see Combining with FFS overview.

Scope

This page is surgeon selection and cost only. Procedure technique, recovery, and dilation live on the per-procedure pages above. Candidacy, letters, and HRT-history requirements live on Candidacy & Timing.

The two-tier market

The market splits cleanly into two tiers, and the distinction matters more than any individual surgeon's marketing or geography.

Tier 1 — high-volume gender-affirming centers. Decades of institutional experience, published cohort outcomes in peer-reviewed urology or plastic surgery journals, and case volumes typically in the range of 100–300+ vaginoplasties per surgeon-year (or per multi-surgeon team). Examples by published series, not endorsement: Mount Sinai (NY), Crane Center (TX), Rumer/McGinn (PA), Bowers' practice (CA), UCSF (CA), Amsterdam UMC/VU (NL), Ghent University Hospital (BE), Chettawut Plastic Surgery and Suporn Clinic (Chonburi, TH), Preecha Aesthetic Institute (Bangkok, TH), and GRS Montréal/Brassard (QC).

Tier 2 — general urology or plastics practices that have begun adopting vaginoplasty. Often a single surgeon doing 10–40 cases per year, no published outcome data, no in-house pelvic floor PT, and nursing staff who learned trans care on the job. These practices proliferated after 2014 (US insurance-coverage expansion under ACA Section 1557) and again after 2022 as WPATH SOC v8 normalized referral pathways.

The volume-outcome relationship is well-documented across reconstructive surgery generally and is widely cited in the vaginoplasty literature as the basis for concentrating cases at experienced centers. The practical implication is that tier matters more than geography or price.

What "high-volume gender-affirming center" actually means

The phrase is used loosely in marketing. A more useful operational definition has five parts; centers that meet all five number in the low dozens worldwide.

1. Published outcome series. Peer-reviewed papers reporting complication rates, neovaginal depth, sexual function, and patient-reported outcomes on the surgeon's or center's own cohort. Not case reports. Not technique descriptions without follow-up. Series of n≥50 with ≥12-month follow-up is the meaningful threshold.
2. Multidisciplinary team. Urology and plastic surgery represented (sometimes a single dual-trained surgeon, more often a pairing). In-house or tightly-integrated pelvic floor physical therapy. A defined pre-op psychological-evaluation pathway. Anesthesiology familiar with long pelvic cases and trans HRT considerations.
3. Trans-experienced nursing. Floor nurses who have managed post-vaginoplasty patients before — packing changes, the first dilation, dilator sizing, distinguishing prolapse from expected granulation, and comfort with trans patients' names and pronouns without prompting.
4. Structured dilation training. A written protocol, in-person teaching by a nurse or PT (not a handout), a specified dilator kit, and a defined follow-up cadence — typical: 1 week, 6 weeks, 3 months, 6 months, 12 months, in-person or telehealth.
5. Revision capacity. Either revises their own complications in-house or has a published referral relationship for revisions. A surgeon who refers all complications elsewhere is a yellow flag.

Credentialing: what the letters mean

Three credentials get cited in marketing copy; only two carry weight.

Credential	What it actually means	Useful as a filter?
Board certification (urology or plastic surgery)	Completed residency, passed board exam, maintains CME. The actual surgical credential.	Yes — minimum bar. US: ABU or ABPS. Equivalents: FRCSC (Canada), FRCS (UK), Royal College certification (Thailand).
Published peer-reviewed series on own cases	Surgeon has shown their outcomes to other surgeons and survived peer review.	Yes — the meaningful indicator of tier-1 status. Search PubMed for [surgeon last name] vaginoplasty; look for n≥50 with ≥12-month follow-up.
WPATH membership	Paid annual dues. No exam, no audit, no outcome reporting.	Low. Necessary for some insurance pathways but not a quality signal on its own.

Board certification plus a published cohort series on the surgeon's own vaginoplasty cases is a tier-1 signal. WPATH membership plus a polished website is not. Fellowship in gender-affirming surgery (a 1-year post-residency program, formalized at several US academic centers since around 2018) is an additional positive signal but is not yet standardized enough to be a hard filter.

Surgeons cited via published technique papers

The list below cites surgeons by their published technique or outcome papers. This is not an endorsement list. Inclusion means the surgeon has put their work in the peer-reviewed record where it can be evaluated. Omission does not mean a surgeon is bad; it means their work is harder to evaluate from outside.

Surgeon (location)	Technique	Representative published work
Marci Bowers (San Mateo, CA)	Penile-inversion vaginoplasty; large series; revision work	Bowers, technique chapters and WPATH proceedings; took over Biber's practice and has reported on cohort volume.
Suporn Watanyusakul / Suporn Clinic (Chonburi, TH)	Non-inversion (Suporn) technique: scrotal-skin canal lining, penile-skin vulva	Watanyusakul, technique descriptions widely cited as the originator of the Suporn approach.
Chettawut Tulayaphanich / Chettawut Plastic Surgery (Bangkok, TH)	Single-stage penile-inversion with scrotal-skin graft augmentation	Chettawut, technique papers and conference series; large single-surgeon volume.
Christine McGinn / Papillon Center (New Hope, PA)	Penile-inversion vaginoplasty; cohort outcomes	McGinn et al., published cohort outcome data in US plastic-surgery literature.
Bouman, van der Sluis, Mullender (Amsterdam UMC/VU)	Penile-inversion and robot-assisted peritoneal vaginoplasty	Bouman et al., laparoscopic sigmoid and peritoneal-flap series; van der Sluis et al., long-term Amsterdam cohort outcomes (program dating to the 1970s).
Garcia, Wittenberg, Nikolavsky and collaborators (UCSF and others)	Robotic peritoneal vaginoplasty (Davydov-derived)	Jacoby, Cohen, Garcia et al., peritoneal vaginoplasty technique and early-outcomes papers in J Urol and Urology.
Loren Schechter (Rush, Chicago)	Penile-inversion technique; gender surgery program building	Schechter, Surgical Management of the Transgender Patient (Elsevier) plus multiple technique and program-design papers.
Curtis Crane / Crane Center (Austin, TX)	Penile-inversion vaginoplasty	Crane et al., published series on PIV outcomes and complications.
Pierre Brassard, Maud Bélanger / GRS Montréal (QC)	Penile-inversion vaginoplasty; very large volume	Brassard et al., Vaginoplasty in Male-to-Female Transsexuals by Inversion of the Penile and Scrotal Skin Flap and follow-up cohort papers.
Preecha Tiewtranon and successors / Preecha Aesthetic Institute (Bangkok)	Penile-inversion vaginoplasty	Tiewtranon, foundational Thai technique papers from the 1980s–90s; institute continues with second-generation surgeons.
Stan Monstrey, Salvatore D'Arpa (Ghent University Hospital, BE)	Penile-inversion and peritoneal	Monstrey et al., long-running Ghent cohort outcome papers, often co-published with Amsterdam.
Rachel Bluebond-Langner, Lee Zhao (NYU Langone)	Robotic peritoneal vaginoplasty; revision	Zhao et al., peritoneal-flap series; Bluebond-Langner, multiple technique and outcomes papers.
Jess Ting (Mount Sinai, NYC)	Penile-inversion and peritoneal	Ting et al., Mount Sinai cohort papers; program established 2016.

The workflow for any surgeon not on this list is the same: search PubMed for [surgeon last name] vaginoplasty. A cohort series with n≥50 and follow-up is tier-1 evidence. Conference abstracts and case reports without follow-up are weaker.

Regional cost ranges (2026)

Ranges are USD-equivalent, surgeon's fee + facility + anesthesia, not including travel, lodging, or post-op support. Year stamp matters.

Region	Procedure	Typical cash price (2026 USD)	Notes
US private	Penile-inversion vaginoplasty	$20,000 – $50,000	Top of range for NYC/SF tier-1 with long-stay aftercare.
US private	Peritoneal vaginoplasty	$25,000 – $60,000	Robotic platform and two-surgeon team push price up.
US private	Vulvoplasty / zero-depth	$15,000 – $40,000	Less common; not all tier-1 centers offer it.
US private	Bilateral orchiectomy	$2,000 – $8,000	Often done by a local urologist; lowest-margin trans surgery.
US insurance	All of the above	Variable; deductible + coinsurance often \(3K–\)15K out of pocket	Coverage is mainstream; out-of-pocket depends on plan structure, not on whether the procedure is "covered." See below.
Thailand	Penile-inversion vaginoplasty	$10,000 – $25,000	Top centers (Suporn, Chettawut, Preecha) at top of range; world-class outcomes documented. Long hotel-stay aftercare bundled in many packages.
Thailand	Peritoneal vaginoplasty	~$18,000 – $30,000	Limited availability; fewer Thai centers offer this.
Canada (public)	Vaginoplasty	$0 patient cost; travel to Montréal often subsidized	2–5+ year wait depending on province. GRS Montréal is the dominant referral.
UK NHS	Vaginoplasty	$0 patient cost	3–7+ year wait via GIC pathway, distributed across Brighton, London, Leeds, Nottingham, Sheffield, Exeter.
UK private	Vaginoplasty	£18,000 – £35,000 (~\(22K–\)45K)	Same surgeons as NHS pathway, faster.
Germany	Vaginoplasty	$0 with statutory insurance	Wait varies by Land; psychiatric assessment requirement is heavier than US/UK.
Netherlands	Vaginoplasty	$0 with basisverzekering	Amsterdam UMC and Radboud are main centers; multi-year wait.
Spain	Vaginoplasty	$0 in some autonomous communities	Coverage by autonomous community (Andalusia, Catalonia, Madrid, others); regional variation is substantial.
Mexico	Vaginoplasty	$8,000 – $18,000	Smaller market; fewer published series. Verify tier carefully.

The Thailand-vs-US gap has narrowed since 2015 as Thai pricing rose and US pricing rose faster. The all-in number for international travel — surgery plus lodging plus 4–8 weeks of out-of-country recovery plus repatriation if a complication arises — is what to compare against a domestic insurance out-of-pocket, not the headline surgical fee.

US insurance documentation playbook

US insurance coverage of vaginoplasty became mainstream after the 2014 ACA non-discrimination interpretation and the 2016 HHS rule (litigated and revised repeatedly since). As of 2026, most large commercial plans, Medicare, and the majority of state Medicaid programs cover vaginoplasty when medical necessity is documented. Out-of-pocket cost depends on deductible, coinsurance, and out-of-network status — not on whether the procedure is nominally "covered."

Documentation packet — assemble before pre-auth request:

1. Medical-necessity letter from the prescribing endocrinologist or primary mental-health provider. Should explicitly reference WPATH SOC v8 (2022) and state that the patient meets criteria: persistent gender dysphoria, capacity to consent, age of majority, other medical conditions reasonably controlled.
2. Second letter from a separate qualified mental-health professional if the plan requires it — some still do despite SOC v8 reducing the formal requirement to one letter for genital surgery.
3. HRT history documenting ≥12 months of continuous gender-affirming hormone therapy (still required by most US payers as of 2026, and by SOC v8 for genital surgery unless contraindicated). See Candidacy & Timing.
4. Surgeon's letter and CPT codes — usually 57335 (vaginoplasty) plus add-ons. The surgeon's billing office handles this.
5. Pre-authorization request submitted by the surgeon's office; expect 30–60 days for response.

Appealing denials. Initial denials are common and often boilerplate ("cosmetic," "experimental"). Both labels are wrong under WPATH SOC v8 and ACA Section 1557 case law.

• Internal appeal within the insurer (deadline usually 180 days from denial). Cite SOC v8, ACA 1557, and any state-level non-discrimination statute (California's Gender Nondiscrimination Act, NY's GENDA, etc.).
• External review by an independent reviewer (state-regulated; ERISA self-funded plans have their own pathway).
• State insurance commissioner complaint for individual and small-group plans.
• Lambda Legal, Transgender Law Center, NCTE maintain attorneys who handle high-leverage appeals; not all cases are taken, but the threat of legal review often resolves a denial.

ACA EHB landscape (2026 status). The Essential Health Benefits framework under the ACA was the subject of regulatory revision in the 2025–2026 cycle, with implications for which gender-affirming services state benchmark plans must cover. The exact final-rule language and effective date have shifted multiple times. Anyone relying on this should verify current CMS guidance and their specific state's benchmark plan rather than assuming coverage from prior-year rules.

Red flags

Patterns associated with worse outcomes or worse patient experience. One is a yellow flag; two or more is a hard pass.

• No published outcomes. Website features testimonials and before/after photos but no peer-reviewed series. Complication rate cannot be evaluated.
• Discourages second opinions. Tier-1 surgeons routinely encourage consultations elsewhere. Pressure not to consult is a sales tactic, not a clinical posture.
• Pressure tactics. "Limited slots," "price increase next month," deposit demanded at first consultation. Real wait lists at high-volume centers are 6–18 months long; nobody needs to pressure-sell.
• No clear post-op support infrastructure. Cannot describe what happens at 1 week, 6 weeks, 6 months. No nurse line. No telehealth follow-up for out-of-town patients. No relationship with pelvic floor PT.
• Unrealistic promises. Specific depth guarantees ("you will have 6 inches"), sensation guarantees, or claims that revisions are never needed. Honest tier-1 surgeons quote ranges and complication rates.
• No revision pathway. "I don't see complications in my practice" is either a lie or a sign of no follow-up.
• Refuses to share complication data, even verbally. A surgeon who has done 200 cases knows their dehiscence rate, granulation rate, stenosis rate. Refusal to discuss is a flag.
• Single-surgeon practice with no team. No PT relationship, no in-house psych support, no urology backup if the surgeon is a plastic surgeon (or vice versa).
• Marketing-heavy, paper-light. Active social media, media appearances, celebrity patients — but no PubMed footprint.

What to ask in a consultation

Concrete questions that surface tier and fit:

1. How many vaginoplasties have you personally performed? In the last 12 months?
2. What is your published series? Where can I read it?
3. What is your major-complication rate (rectovaginal fistula, flap necrosis, stenosis requiring revision)?
4. Who manages my care if I have a complication at 3 months and I live 1,000 miles away?
5. Who teaches dilation, when, and what dilator set do you use?
6. What is your relationship with pelvic floor PT — in-house, referral, or none?
7. If I need a revision, do you do it or refer out? At what cost?
8. What is the realistic depth range for my anatomy? (A surgeon who answers "everyone gets 6 inches" is not being honest.)
9. Can I speak to former patients at 1 year and 5 years post-op?
10. What does your follow-up cadence look like for out-of-town patients?

For patients combining bottom surgery with facial work, sequencing is its own decision — see Combining with FFS overview.

Community resources

Word-of-mouth in this space moves fast and recommendations age within 12–24 months as surgeons retire, change practices, or change caseload mix. This wiki does not name specific surgeons as endorsements. The following are active channels where current word-of-mouth circulates. Treat all such forums as opinionated, anonymous, and partly astroturfed by clinics — read broadly, not narrowly.

• r/Transgender_Surgeries and r/TransgenderSurgeries (Reddit). Search the surgeon's name plus "vaginoplasty" or "PIV."
• r/MtF, r/asktransgender — broader threads, lower signal-to-noise.
• TransHealthcare.org maintains a surgeon directory with patient-submitted reviews; coverage of bottom surgery is the strongest section of the site.
• Trans-care Discord servers. Several invite-only servers maintain surgeon-recommendation channels with searchable review histories. Asking on r/Transgender_Surgeries usually surfaces current invite links.

Cross-reference any recommendation across at least two channels and confirm the surgeon has a non-trivial published track record before committing to a deposit.

Sources

• Coleman E. et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgender Health 2022;23(S1). WPATH SOC8.
• Brassard P., Bélanger M. et al. Vaginoplasty in Male-to-Female Transsexuals by Inversion of the Penile and Scrotal Skin Flap, Plast Reconstr Surg, and follow-up cohort papers. PubMed: Brassard vaginoplasty.
• Bouman M-B., van der Sluis W., Mullender M. et al. Amsterdam UMC/VU peritoneal and PIV cohort papers; long-term outcome series. PubMed: Bouman vaginoplasty, van der Sluis vaginoplasty.
• Jacoby A., Cohen J., Garcia M. et al. Robotic peritoneal vaginoplasty (Davydov-derived) outcomes, J Urol and Urology. PubMed: peritoneal vaginoplasty robotic.
• Schechter L. S. Surgical Management of the Transgender Patient (Elsevier); program-design and technique papers. PubMed: Schechter gender surgery.
• Crane C. et al. Penile-inversion vaginoplasty cohort outcomes. PubMed: Crane vaginoplasty.
• Monstrey S., D'Arpa S. et al. Ghent cohort outcome papers, often joint with Amsterdam. PubMed: Monstrey vaginoplasty.
• Zhao L. C., Bluebond-Langner R. et al. NYU peritoneal vaginoplasty technique and revision series. PubMed: Zhao Bluebond-Langner vaginoplasty.
• Ting J. et al. Mount Sinai vaginoplasty cohort. PubMed: Ting Mount Sinai vaginoplasty.
• McGinn C. et al. Papillon Center cohort outcomes. PubMed: McGinn vaginoplasty.
• Bowers M. L. Technique chapters and WPATH proceedings. PubMed: Bowers M vaginoplasty.
• American Board of Urology (ABU) and American Board of Plastic Surgery (ABPS) — the meaningful US surgical credentials.
• ACA Section 1557 / 45 CFR 92 non-discrimination regulations; HHS Office for Civil Rights guidance (revised multiple times 2016–2026 — verify current version).
• CMS Essential Health Benefits benchmark-plan guidance, 2025–2026 rulemaking cycle. STALE/VERIFY.
• Lambda Legal, Transgender Law Center, National Center for Transgender Equality — published insurance-appeal templates and case-law summaries.
• Volume-outcome relationship in reconstructive surgery: foundational papers by Birkmeyer, Halm, et al. on hospital and surgeon volume vs. outcome underlie the tier-1/tier-2 framing here. Vaginoplasty-specific volume-outcome studies are limited but emerging — PubMed: vaginoplasty volume outcome.